Rohit Malik

o Responsible for driving the development and expansion of oncology and immunology portfolios by providing critical scientific and strategic insights. o Leading cross-functional teams to successfully advance and deliver initiatives within the small molecule drug portfolio. o Acting as a functional area expert, spearheading novel initiatives to foster innovation and progress in drug discovery. o Evaluate and pursue external business development opportunities to strategically enhance and broaden the oncology and immunology pipelines.

o Responsible for providing scientific, business, and strategic vision for the Cancer Biology Group within the tumor microenvironment thematic research center. o Leading a team of ~11 scientists, including Ph.D. level program team leaders and bench scientists, and effectively collaborating with cross-functional team leaders to develop and execute an integrated strategy. o Demonstrated ability to successfully guide and ensure the transition of innovative targets from hit discovery, hit-to-lead, lead optimization through to human proof-of-mechanism (PoM) and proof-of-concept (PoC) evaluation. o Acting as a subject-matter expert in the evaluation of external opportunities in collaboration with business development teams, including asset-level diligence and the evaluation of novel technologies or platforms that complement our drug discovery and translational capabilities. o Actively managing a small molecule oncology and immune-oncology portfolio spanning multiple modalities including molecular glue (CELMoD), heterobifunctional degraders, and small molecule enzymatic and allosteric inhibitors with either first- or best-in-class potential in well-defined patient settings. o Leading the company-wide integrated prostate cancer tumor strategy team as a discovery biology representative to design strategy for prostate tumors by interacting with KOLs, and clinical, commercial, and business development organizations. o Leading multiple high-impact academic and industry collaborations to support portfolio programs and identify novel therapeutic targets.

 Identified and characterized the role of mixed-lineage leukemia protein (MLL) complex in androgen receptor signaling and investigated therapeutic potential of menin-MLL complex inhibitors in lethal castration-resistant prostate cancer (CRPC) (Nature Medicine, 2015).  Executed discovery and characterization of ARlnc-1, a highly prostate cancer-specific lncRNA, (Nature Genetics, 2018). Identified PCAT-14, a novel prostate cancer and lineage-specific long non-coding RNAs as a prognostic biomarker for treatment intensification in prostate cancer (Neoplasia, 2016)  Investigated in-vitro and in-vivo efficacy as well as the mechanism of action of BET degrader molecule in prostate cancer (Nature, 2014). Initiated studies to understand the mechanism of acquired resistance to anti-androgen and anti-BET therapies in prostate cancer.  Led and managed a large team of scientists (Graduate Students, Post-doctoral Fellows, Research technicians, and Undergraduate Students) to evaluate the role of long non-coding RNA in cancer biology. Highly experienced in the training, supervision, and development of scientists at various levels.  Authored several research articles and successfully competed and obtained extramural funding to develop therapeutics for CRPC. Responsible for conceptualization, preparing grant applications, implementation of funded research, and preparing annual reports for funding agencies.

Mentor: Dr. Arul Chinnaiyan  Investigated the role of novel cancer-associated long non-coding RNAs in prostate cancer initiation and progression, and evaluated therapeutic and biomarker potential of these lncRNA in several cancer types (Mol. Can. Res. 2014)  Collaborated with bioinformatics scientists to develop a catalog of long non-coding RNA using pan-cancer transcriptomics dataset (Nature Genetics 2015)  Received postdoctoral funding from the Department of Defense to study the role of lncRNAs in CRPC.

 Demonstrated the role of Post-translational modification (Ubiquitination, Phosphorylation, and SUMOylation) in the regulation of G-protein coupled receptors (CXCR4 and β-adrenergic receptor). (Mol Bio. Cell 2010; J Bio Chem 2011, J Bio Chem 2012)  Established a role for protein Geminin in breast cancer pathogenesis (Oncotargets 2011; Breast Can. Res 2011)  Authored five first author articles peer-reviewed journals.  Secured pre-doctoral funding from the American Heart Association to study the mechanism of CXCR4 regulation.

Helped to manage DNA fingerprinting lab of the Central Forensic Science Laboratories (C.F.S.L.), India. Job responsibilities included performing 15 loci autosomal and Y-STR DNA analysis for human DNA identification as well as generating data for autosomal and Y-STR markers in Indian population for evolution studies.

To understand the mechanisms underlying signaling and trafficking of CXCR4, a chemokine receptor involved in immune cell trafficking and cancer metastasis.